Ansicht: Klassisch | Themen | Beiträge |

Depression

Tom schrieb am 4. März 2004 um 19:15 Uhr (1041x gelesen):

Die Depression, gekennzeichnet durch unglückliche Gefühle der Hoffnungslosigkeit, kann eine Antwort auf folgende Störfaktoren bzw. Maengel sein:
Stress,
hormonale Ungleichheiten,
biochemische Abweichungen,
verringerte Schildrüsenfunktion,
Nahrungsmittelallergien,
orale Contraceptiva (Pille),
prämenstruelles Sydrom,
Eisenmangel,
Vitamin B-Mangel (B1, B6, B12, Folsäure), ferner B2, B3, B5, Biotin,
Omega 3 Fettsäure (DHA),
Aminosäuren Tyrosin, L-Phenylalanin,
DHEA-Mangel,
Minderdurchblutung des frontalen Hirnlappen (nach Uni-Klinik-Innsbruck)
Jodunverträglichkeit,
kranker Darm (z.B. Pilze),
Unterzucker,
Alkohol,
Wohngifte,
geopathogene Störzonen,
Amalgam,
Elektrosmog,
Viren,
Medikamente (siehe „Die Vitaminbibel“),
Was können Betroffene selbst tun ?! (www.selen-forum.de)
Wichtig ist die Erkenntnis erkrankt zu sein, Hilfe zu akzeptieren, diese aber auch selbst aktiv
zu unterstützen.
Denn nur wer erkennt, dass er ohne eigenes zutun nichts erreicht, dem können Arzt, Familie und Freunde helfen.
Zu erkennen, Stress zu meiden und diesen zu umgehen, ist wichtig.
Der erste Schritt ist Ehrlichkeit vor sich selbst.
Wenn ich dies geschafft habe, muss ich den ersten wichtigen Schritt nach außen tun und mich jemandem anvertrauen.
Dies ist der erste aber auch zugleich wohl der schwerste Schritt nach außen.
Literatur:
Earl Mindell, Die Vitaminbibel,
Anne Calatin, Zeitkranheit Nahrungsmittel-Allergien,
References aus Forum “Depression and alternativ-medicin”:
1. Gettis A. Food sensitivities and psychological disturbance: a review. Nutr Health 1989;6:135–46.
2. King DS. Can allergic exposure provoke psychological symptoms? A double-blind test. Biol Psychiatr 1981;16:3–19.
3. Brown M, Gibney M, Husband PR, Radcliffe M. Food allergy in polysymptomatic patients. Practitioner 1981;225:1651–54.
4. Christensen L. Psychological distress and diet-effects of sucrose and caffeine. J Applied Nutr 1988;40:44–50.
5. Greden JF, Fontaine P, Lubetsky M, Chamberlin K. Anxiety and depression associated with caffeinism among psychiatric inpatients. Am J Psychiatry 1978;135:963–66.
6. Kawachi I, Willett WC, Colditz GA, Stampfer MJ, Speizer FE. A prospective study of coffee drinking and suicide in women. Arch Intern Med 1996;156:521–25.
7. Gilliland K, Bullock W. Caffeine: a potential drug of abuse. Adv Alcohol Subst Abuse 1983-84;3:53–73.
8. Martinsen EW. Benefits of exercise for the treatment of depression. Sports Med 1990;9:380–89.
9. Martinsen EW, Medhus A, Sandivik L. Effects of aerobic exercise on depression: a controlled study. BMJ 1985;291:109.
10. Adams PW, Wynn V, Rose DP, et al. Effect of pyridoxine hydrochloride (Vitamin B6) upon depression associated with oral contraception. Lancet 1973;I:897–904.
11. Russ CS, Hendricks TA, Chrisley BM, et al. Vitamin B-6 status of depressed and obsessive-compulsive patients. Nutr Rep Internat 1983;27:867–73.
12. Gunn ADG. Vitamin B6 and the premenstrual syndrome (PMS). Int J Vitam Nutr Res 1985;(Suppl 27):213–24 [review].
13. Kleijnen J, Riet GT, Knipschild P. Vitamin B6 in the treatment of the premenstrual syndrome—a review. Brit J Obstet Gynaecol 1990;97:847–52.
14. Lindenbaum J, Healton EB, Savage DG, et al. Neuropsychiatric disorders caused by cobalamin deficiency in the absence of anemia or macrocytosis. N Engl J Med 1988;318:1720–28.
15. Holmes JM. Cerebral manifestations of vitamin B12 deficiency. J Nutr Med 1991;2:89–90.
16. Ellis FR, Nasser S. A pilot study of vitamin B12 in the treatment of tiredness. Br J Nutr 1973;30:277–83.
17. Reynolds E et al. Folate deficiency in depressive illness. Br J Psychiatr 1970;117:287–92.
18. Coppen A, Chaudrhy S, Swade C. Folic acid enhances lithium prophylaxis. J Affective Disorders 1986;10:9–13.
19. Di Palma C, Urani R, Agricola R, et al. Is methylfolate effective in relieving major depression in chronic alcoholics? A hypothesis of treatment. Curr Ther Res 1994;55:559–67.
20. Edwards R, Peet M, Shay J, Horrobin D. Omega-3 polyunsaturated fatty acid levels in the diet and in red blood cell membranes of depressed patients. J Affect Disord 1998;48:149–55.
21. Adams PB, Lawson S, Sanigorski A, Sinclair AJ. Arachidonic acid to eicosapentaenoic acid ratio in blood correlates positively with clinical symptoms of depression. Lipids 1996;31:S-157–S-161.
22. Rose DP, Cramp DG. Reduction of plasma tyrosine by oral contraceptives and oestrogens: a possible consequence of tyrosine aminotransferase induction. Clin Chem Acta 1970;29:49–53.
23. Moller SE. Tryptophan and tyrosine availability and oral contraceptives. Lancet 1979;ii:472 [letter].
24. Kishimoto H, Hama Y. The level and diurnal rhythm of plasma tryptophan and tyrosine in manic-depressive patients. Yokohama Med Bull 1976;27:89–97.
25. Gelenberg AJ, Wojcik JD, Growdon JH, et al. Tyrosine for the treatment of depression. Am J Psychiatr 1980;137:622–23.
26. Sabelli HC, Fawcett J, Gustovsky F, et al. Clinical studies on the phenylethylamine hypothesis of affective disorder: urine and blood phenylacetic acid and phenylalanine dietary supplements. J Clin Psychiatr 1986;47:66–70.
27. Sabelli HC, Fawcett J, Gustovsky F, et al. Clinical studies on the phenylethylamine hypothesis of affective disorder: urine and blood phenylacetic acid and phenylalanine dietary supplements. J Clin Psychiatr 1986;47:66–70.
28. Beckman H, Strauss MA, Ludolph E. DL-Phenylalanine in depressed patients: an open study. J Neural Transmission 1977;41:123–34.
29. Beckmann H, Athen D, Olteanu M, Zimmer R. DL-phenylalanine versus imipramine: a double-blind controlled study. Arch Psychiatr Nervenkr 1979;227:49–58.
30. Maggioni M, Picotti GB, Bondiolotti GP, et al. Effects of phosphatidylserine therapy in geriatric patients with depressive disorders. Acta Psychiatr Scand 1990;81:265–70.
31. Wolkowitz OM, et al. Dehydroepiandrosterone (DHEA) treatment of depression. Biol Psychiatr 1997;41:311–18.
32. Wolkowitz OW, Reus VI, Keebler A, et al. Double-blind treatment of major depression with dehydroepiandrosterone. Am J Psychiatry 1999;156:646–49.
33. Barkai AI, Dunner DL, Gross HA, et al. Reduced myo-inositol levels in cerebrospinal fluid from patients with affective disorder. Biol Psych 1978;13:65–72.
34. Birkmayer JGD, Birkmayer W. The coenzyme nicotinamide adenine dinucleotide (NADH) as biological antidepressive agent: Experience with 205 patients. New Trends Clin Neuropharmacol 1991;5:19–25.
35. Bell KM, Potkin SG, Carreon D, Plon L. S-adenosylmethionine blood levels in major depression: changes with drug treatment. Acta Neurol Scand 1994;154(suppl):15–18.
36. Bressa GM. S-adenosyl-l-methionine (SAMe) as antidepressant: Meta-analysis of clinical studies. Acta Neurol Scand 1994;154(suppl):7–14.
37. Salmaggi P, Bressa GM, Nicchia G, et al. Double-blind, placebo-controlled study of s-adenosyl-methionine in depressed post-menopausal women. Psychotherapy & Psychosomatics 1993;59:34–40.
38. Kagan BL, Sultzer DL, Rosenlicht N, et al. Oral S-adenosyl-methionine in depression: A randomized, double-blind, placebo-controlled trial. Am J Psychiatr 1990;147:591–95.
39. Fava M, Rosenbaum JF, Birnbaum R, et al. The thyrotropin-releasing hormone as a predictor of response to treatment in depressed outpatients. Acta Psychiatr Scand 1992;86:42–45.
40. De Vanna M, Rigamonti R. Oral S-adenosyl-L-methionine in depression. Curr Ther Res 1992;52:478–85.
41. Van Praag HM, Lemus C. Monoamine precursors in the treatment of psychiatric disorders. Nutrition and the Brain, vol. 7, eds. RJ Wurtman, JJ Wurtman. New York: Raven Press, 1986 [review].
42. Van Praag H, de Hann S. Depression vulnerability and 5-hydroxytryptophan prophylaxis. Psychiatry Res 1980;3:75–83.
43. Angst J, Woggon B, Schoepf J. The treatment of depression with L-5-hydroxytryptophan versus imipramine. Results of two open and one double-blind study. Arch Psychiatr Nervenkr 1977;224:175–86.
44. Nolen WA, van de Putte JJ, Dijken WA, et al. Treatment strategy in depression. II. MAO inhibitors in depression resistant to cyclic antidepressants: two controlled crossover studies with tranylcypromine versus L-5-hydroxytryptophan and nimifensine. Acta Psychiatr Scand 1988;78:676–83.
45. Nolen WA, van de Putte JJ, Dijken WA, Kamp JS. L-5-HTP in depression resistant to re-uptake inhibitors. An open comparative study with tranylcypromine. Br J Psychiatry 1985;147:16–22.
46. D’Elia G, Hanson L, Raotma H. L-tryptophan and 5-hydroxytryptophan in the treatment of depression. A review. Acta Psychiatr Scand 1978;57:239–52 [review].
47. Harrer G, Sommer H. Treatment of mild/moderate depressions with Hypericum. Phytomedicine 1994;1:3–8.
48. Ernst E. St. John’s wort, an antidepressant? A systemic, criteria-based review. Phytomedicine 1995;2:67–71.
49. Vorbach EU, Hübner WD, Arnoldt KH. Effectiveness and tolerance of the Hypericum extract LI 160 in comparison with imipramine: Randomized double-blind study with 135 outpatients. J Ger Psychiatr Neurol 1994;7(suppl):S19–S23.
50.Wheatley D. LI 160, an extract of St. John’s wort versus amitriptyline in mildly to moderately depressed outpatients—controlled six week clinical trial. Pharmacopsychiatry 1997;30(suppl):77–80.
51. Harrer G, Hübner WD, Poduzweit H. Effectiveness and tolerance of the Hypericum extract LI 160 compared to maprotiline: A multicenter double-blind study. J Ger Psychiatr Neurol 1994;7(suppl 1);S24–S28.
52.Vorbach EU, Arnoldt KH, Hübner WD. Efficacy and tolerability of St. John’s wort extract LI 160 versus imipramine in patients with severe depressive episodes according to ICD-10. Pharmacopsychiatry 1997;30(suppl):81–85.
53. Blumenthal M, Busse WR, Goldberg A, et al, eds. The Complete Commission E Monographs: Therapeutic Guide to Herbal Medicines. Boston, MA: Integrative Medicine Communications, 1998, 214–15.
54. Chatterjee SS, Bhattacharya SK, Wonnemann M, et al. Hyperforin as a possible antidepressant components of hypericum extracts. Life Sci 1998;63:499–510.
55. Schubert H, Halama P. Depressive episode primarily unresponsive to therapy in elderly patients; efficacy of Ginkgo biloba extract (EGb 761) in combination with antidepressants. Geriatr Forsch 1993;3:45–53.

  Beitrag ist archiviert